Core Viewpoint - The company plans to utilize temporarily idle raised funds for cash management to enhance fund efficiency and generate additional returns for the company and its shareholders [3][9][18]. Investment Overview - Investment Purpose: The aim is to improve the efficiency of raised fund usage while ensuring that it does not affect the construction and use of the raised fund projects [3]. - Investment Amount: The company intends to use up to RMB 300 million (including principal) for cash management, with a validity period of 12 months from the board's approval [4][14]. - Source of Funds: The funds for this cash management initiative come from the temporarily idle raised funds from the company's initial public offering in 2019 [5]. Investment Details - Investment Products: The company will invest in low-risk, liquid, and capital-protected financial products, including but not limited to agreement deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [2][10]. - Implementation Method: The board authorizes the management to make investment decisions within the approved limits and timeframe, with the finance department responsible for execution [11][14]. Recent Cash Management Situation - The company has previously authorized cash management of up to RMB 400 million, with the latest authorization allowing for up to RMB 300 million [13][26]. Impact on the Company - The planned cash management will not affect the normal operation of the company's main business or the normal turnover of funds, and it aims to generate investment returns for the company and its shareholders [18][20]. Sponsor's Verification Opinion - The sponsor, UBS Securities, has confirmed that the cash management initiative has been approved by the board and complies with relevant laws and regulations, ensuring that it does not alter the intended use of raised funds [19][20].
上海昊海生物科技股份有限公司关于使用暂时闲置募集资金进行现金管理的公告